Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

NCT00836927 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancers

Interventions

DRUG: Ridaforolimus Tablet
DRUG: Ridaforolimus Intravenous (IV) Infusion

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]